What the new Argentina guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Side effects
Incidence in the trial populations, mechanism where it is known, and management where it is supported.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
What the anaesthetists said, and then said again
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
The restart nobody plans for
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Poland pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Do you need the top of the ladder?
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
What STEP 4 and SURMOUNT-4 actually established
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
The tolerability data everybody quotes and nobody reads
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
What the new the United Kingdom guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Denmark pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The eighteenth month, and the conversation that should have happened in the third
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
The eighteenth month, and the conversation that should have happened in the third
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Japan pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Forty-four per cent: reading the nausea figure properly
Almost every figure in circulation about tolerability comes from six publications. This is what they say.